Citations (57)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yue Zhao, Xiaolei Wang, Yuanxi Huang, Xianli Zhou & Dongwei Zhang. (2019) Conversion of immunohistochemical markers and breast density are associated with pathological response and prognosis in very young breast cancer patients who fail to achieve a pathological complete response after neoadjuvant chemotherapy. Cancer Management and Research 11, pages 5677-5690.
Read now
Read now
Ana M Angarita, Diana Cholakian & Amanda N Fader. (2015) Low-grade serous carcinoma: molecular features and contemporary treatment strategies. Expert Review of Anticancer Therapy 15:8, pages 893-899.
Read now
Read now
Articles from other publishers (55)
Cansu Karakas, Haley Tyburski, Bradley M. Turner, Anna Weiss, Sajal Medha K. Akkipeddi, Ajay Dhakal, Kristin Skinner, David G. Hicks & Huina Zhang. (2023) HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low category. Human Pathology 142, pages 34-41.
Crossref
Crossref
Sudheer Vemuru, Jin Huang, Kathryn Colborn, YooJin Yoon, Victoria Huynh, Laura Leonard, Gretchen Ahrendt, Nicole Christian, Anosheh Afghahi, Lauren McLemore, Sharon Sams & Sarah Tevis. (2023) Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy. Breast Cancer Research and Treatment 200:2, pages 247-256.
Crossref
Crossref
Chenyang Li, Zhangyan Lyu, Zhipeng Wang, Chunfang Hao, Yubei Huang & Fengju Song. (2023) The changes of subtype markers between first and second primary breast cancers. Cancer Medicine 12:12, pages 13649-13660.
Crossref
Crossref
Yang He, Jing Zhang, Hui Chen, Ying Zhou, Liping Hong, Yue Ma, Nannan Chen, Weipeng Zhao & Zhongsheng Tong. (2023) Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients. Frontiers in Surgery 9.
Crossref
Crossref
Faina Nakhlis, Leah Portnow, Eva Gombos, Ayse Ece Cali Daylan, Jose Pablo Leone, Olga Kantor, Edward T. Richardson, Alice Ho, Samantha Armstrong Dunn & Nisha Ohri. (2022) Multidisciplinary considerations in the management of breast cancer patients receiving neoadjuvant chemotherapy. Current Problems in Surgery 59:9, pages 101191.
Crossref
Crossref
Ailin Lan, Yudi Jin, Yu Wang, Nan Ding, Yihua Wang, Yuran Dai, Linshan Jiang, Zhenrong Tang, Yang Peng & Shengchun Liu. (2022) Association of serum reproductive hormones changes after neoadjuvant chemotherapy with hormone receptors expression alterations and survival outcomes in breast cancer. Frontiers in Surgery 9.
Crossref
Crossref
Octavio Burgués, Liria Terrádez, Elvira Buch, Mª. Teresa Martínez, Juan Miguel Cejalvo & Begoña Bermejo. (2022) Tratamiento neoadyuvante en el cáncer de mama. El papel del patólogo. Revista de Senología y Patología Mamaria 35, pages S87-S100.
Crossref
Crossref
Sunati Sahoo, Gregor Krings, Yunn-Yi Chen, Jodi M. Carter, Beiyun Chen, Hua Guo, Hanina Hibshoosh, Emily Reisenbichler, Fang Fan, Shi Wei, Laila Khazai, Ronald Balassanian, Molly E. Klein, Sonal Shad, Sara J. Venters, Alexander D. Borowsky, W. Fraser Symmans & I. Tolgay Ocal. (2022) Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy. Archives of Pathology & Laboratory Medicine 147:5, pages 591-603.
Crossref
Crossref
Amarjeet SinghNeeraj KumarNagendra Singh BhadauriaRaj Govind SharmaAmit Singh. (2022) A DESCRIPTIVE OBSERVATIONAL STUDY OF DIFFERENCE OF ESTROGEN & PROGESTERONE RECEPTOR STATUS BEFORE AND AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER. INDIAN JOURNAL OF APPLIED RESEARCH, pages 1-4.
Crossref
Crossref
Sharlene Helene C. See & Kalliopi P. Siziopikou. (2022) Pathologic evaluation of specimens after neoadjuvant chemotherapy in breast cancer: Current recommendations and challenges. Pathology - Research and Practice 230, pages 153753.
Crossref
Crossref
Cristina Zarotti, Bärbel Papassotiropoulos, Constanze Elfgen, Konstantin Dedes, Denise Vorburger, Bernhard Pestalozzi, Andreas Trojan & Zsuzsanna Varga. (2022) Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy. Scientific Reports 12:1.
Crossref
Crossref
Abeer M. Shaaban & Elena Provenzano. (2022) Receptor Status after Neoadjuvant Therapy of Breast Cancer: Significance and Implications. Pathobiology 89:5, pages 297-308.
Crossref
Crossref
Gabrielle M. Baker. 2022. Management of the Breast and Axilla in the Neoadjuvant Setting. Management of the Breast and Axilla in the Neoadjuvant Setting
19
45
.
Imam Hafidh Zaini, Widyanti Soewoto & Ida Bagus Budhi. (2021) The Effect of Chemotherapy on Estradiol Levels in Patients with HER 2-Overexpression Breast Cancer in Dr Moewardi General Hospital, Surakarta, Indonesia. Open Access Macedonian Journal of Medical Sciences 9:B, pages 1570-1574.
Crossref
Crossref
Janitta Kundaikar, Shaji Thomas, Kiran Aggarwal, O. P. Pathania & Manoj Andley. (2021) Effect of Neoadjuvant Chemotherapy on Hormone and Her2neu Receptor Expression in Breast Cancer Patients—a Prospective Cohort Study. Indian Journal of Surgery 83:S2, pages 504-510.
Crossref
Crossref
Heba F. Taha, Ola M. Elfarargy, Reham A. Salem, Doaa Mandour, Amira A. Salem & Mohamed Riad. (2021) Concordance Between ER, PR, HER2 neu Receptors Before and After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Forum of Clinical Oncology 12:1, pages 3-11.
Crossref
Crossref
Khalid Al-Saleh, Tareq Salah, Maria Arafah, Sufia Husain, Ammar Al-Rikabi & Nashwa Abd El-Aziz. (2021) Prognostic significance of estrogen, progesterone and HER2 receptors’ status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia. PLOS ONE 16:3, pages e0247802.
Crossref
Crossref
Rachel HanSteffi RegpalaElzbieta SlodkowskaSharon Nofech-MozesWedad HannaCarlos Parra-HerranFang-I Lu. (2020) Lack of Standardization in the Processing and Reporting of Post-Neoadjuvant Breast Cancer Specimens. Archives of Pathology & Laboratory Medicine 144:10, pages 1262-1270.
Crossref
Crossref
Katarína Petráková. (2020) Residual disease after neoadjuvant systemic anti-HER2 therapy: the KATHERINE trial. Onkologie 14:2, pages 93-95.
Crossref
Crossref
Soomin Ahn, Ji Won Woo, Kyoungyul Lee & So Yeon Park. (2020) HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. Journal of Pathology and Translational Medicine 54:1, pages 34-44.
Crossref
Crossref
Sonali Lanjewar, Priyanka Patil & Susan Fineberg. (2020) Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy—a survey of pathologists in academic institutions across the United States. Modern Pathology 33:1, pages 91-98.
Crossref
Crossref
Luigi Rossi, Monica Verrico, Silverio Tomao, Fabio Ricci, Antonella Fontana, Gian Paolo Spinelli, Maria Colonna, Patrizia Vici & Federica Tomao. (2019) Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy. Cancer Chemotherapy and Pharmacology 85:1, pages 105-111.
Crossref
Crossref
Chao Li, Hongwei Fan, Qian Xiang, Ling Xu, Zhuo Zhang, Qianxin Liu, Tongtong Zhang, Jinjie Ling, Ying Zhou, Xia Zhao & Yimin Cui. (2019) Prognostic value of receptor status conversion following neoadjuvant chemotherapy in breast cancer patients: a systematic review and meta-analysis. Breast Cancer Research and Treatment 178:3, pages 497-504.
Crossref
Crossref
Gabrielle M. Baker, Tari A. King & Stuart J. Schnitt. (2019) Evaluation of Breast and Axillary Lymph Node Specimens in Breast Cancer Patients Treated With Neoadjuvant Systemic Therapy. Advances in Anatomic Pathology 26:4, pages 221-234.
Crossref
Crossref
Miralem Mrkonjic, Hal K Berman, Susan J Done, Bruce Youngson & Anna Marie Mulligan. (2019) Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances. Journal of Clinical Pathology 72:2, pages 120-132.
Crossref
Crossref
Xinyan Li, Mozhi Wang, Mengshen Wang, Xueting Yu, Jingyi Guo, Tie Sun, Litong Yao, Qiang Zhang & Yingying Xu. (2019) Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy. Journal of Breast Cancer 22:4, pages 497.
Crossref
Crossref
Libo Yang, Xiaorong Zhong, Tianjie Pu, Yan Qiu, Feng Ye & Hong Bu. (2018) Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy. World Journal of Surgical Oncology 16:1.
Crossref
Crossref
Lucy M. De La Cruz, Michael O. Harhay, Paul Zhang & Stacy Ugras. (2018) Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How?. Annals of Surgical Oncology 25:12, pages 3535-3540.
Crossref
Crossref
Soomin Ahn, Hyun Jeong Kim, Milim Kim, Yul Ri Chung, Eunyoung Kang, Eun-Kyu Kim, Se Hyun Kim, Yu Jung Kim, Jee Hyun Kim, In Ah Kim & So Yeon Park. (2018) Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer. Cancer Research and Treatment 50:4, pages 1418-1432.
Crossref
Crossref
Phil Townend, Phil R. de Reuver, Terence C. Chua, Anubhav Mittal, Stephen J. Clark, Nick Pavlakis, Anthony J. Gill & Jaswinder S. Samra. (2018) Histopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data. ANZ Journal of Surgery 88:3, pages E167-E172.
Crossref
Crossref
O. Burgués, Mª. Á. López-García, B. Pérez-Míes, P. Santiago, B. Vieites, J. F. García & V. Peg. (2017) The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience. Clinical and Translational Oncology 20:3, pages 382-391.
Crossref
Crossref
Shetal A. Patel & Angela DeMichele. (2017) Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data. Current Oncology Reports 19:8.
Crossref
Crossref
Yong Joon Suh, Hyukjai Shin & Tae Jung Kwon. (2017) Natural History of Invasive Papillary Breast Carcinoma Followed for 10 Years: A Case Report and Literature Review. Case Reports in Medicine 2017, pages 1-4.
Crossref
Crossref
Elena Provenzano & Sarah E Pinder. (2017) Modern therapies and iatrogenic changes in breast pathology. Histopathology 70:1, pages 40-55.
Crossref
Crossref
Ruo-Xi Wang, Sheng Chen, Xi Jin, Can-Ming Chen & Zhi-Ming Shao. (2016) Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis. Breast Cancer Research and Treatment 161:2, pages 259-267.
Crossref
Crossref
Elena Provenzano. 2017. Breast Pathology. Breast Pathology
11
32
.
Begoña Vieites, María Á López-García, Carolina Castilla, María J Hernández, Michele Biscuola, Lina Alfaro, María R Atienza, María Á Castilla & José Palacios. (2016) CK19 expression in breast tumours and lymph node metastasis after neoadjuvant therapy. Histopathology 69:2, pages 239-249.
Crossref
Crossref
Frederique Penault-Llorca & Nina Radosevic-Robin. (2016) Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nature Reviews Clinical Oncology 13:8, pages 487-503.
Crossref
Crossref
Toru Ogura & Takemi Yanagimoto. (2016) Improving and extending the McNemar test using the Bayesian method. Statistics in Medicine 35:14, pages 2455-2466.
Crossref
Crossref
Yukie Enomoto, Takashi Morimoto, Arisa Nishimukai, Tomoko Higuchi, Ayako Yanai, Yoshimasa Miyagawa, Keiko Murase, Michiko Imamura, Yuichi Takatsuka, Takashi Nomura, Masashi Takeda, Takahiro Watanabe, Seiichi Hirota & Yasuo Miyoshi. (2015) Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers. International Journal of Clinical Oncology 21:2, pages 254-261.
Crossref
Crossref
Siew Kuan Lim, Moo Hyun Lee, In Hae Park, Ji Young You, Byung-Ho Nam, Byeong Nam Kim, Jungsil Ro, Keun Seok Lee, So-Youn Jung, Young Mee Kwon & Eun Sook Lee. (2016) Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome. Cancer Research and Treatment 48:1, pages 133-141.
Crossref
Crossref
Xingchen Zhou, Junyong Zhang, Haiqin Yun, Ranran Shi, Yan Wang, Wei Wang, Svetlana Bajalica Lagercrantz & Kun Mu. (2015) Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration. Oncotarget 6:34, pages 36894-36902.
Crossref
Crossref
Elena Provenzano, Veerle Bossuyt, Giuseppe Viale, David Cameron, Sunil Badve, Carsten Denkert, Gaëtan MacGrogan, Frédérique Penault-Llorca, Judy Boughey, Giuseppe Curigliano, J Michael Dixon, Laura Esserman, Gerd Fastner, Thorsten Kuehn, Florentia Peintinger, Gunter von Minckwitz, Julia White, Wei Yang & W Fraser Symmans. (2015) Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Modern Pathology 28:9, pages 1185-1201.
Crossref
Crossref
V. Bossuyt, E. Provenzano, W.F. Symmans, J.C. Boughey, C. Coles, G. Curigliano, J.M. Dixon, L.J. Esserman, G. Fastner, T. Kuehn, F. Peintinger, G. von Minckwitz, J. White, W. Yang, S. Badve, C. Denkert, G. MacGrogan, F. Penault-Llorca, G. Viale, D. Cameron, Helena Earl, Emilio Alba, Ana Lluch, Joan Albanell, Keith Amos, Wojciech Biernat, Hervé Bonnefoi, Aman Buzdar, Paul Cane, Sarah Pinder, Lesley Carson, Diana Dickson-Witmer, Gyungyub Gong, Jimmy Green, Chih-Yi Hsu, Ling-Ming Tseng, Judith Kroep, A. Marilyn Leitch, Venetia Sarode, Eleftherios Mamounas, Paul Kelly Marcom, Paolo Nuciforo, Soonmyung Paik, Vicente Peg, David Peston, Jean-Yves Pierga, Miguel Quintela-Fandino, Roberto Salgado, William Sikov, Jeremy Thomas, Gary Unzeitig & Jelle Wesseling. (2015) Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Annals of Oncology 26:7, pages 1280-1291.
Crossref
Crossref
Xi Jin, Yi-Zhou Jiang, Sheng Chen, Ke-Da Yu, Zhi-Ming Shao & Gen-Hong Di. (2015) Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study. Oncotarget 6:11, pages 9600-9611.
Crossref
Crossref
Xi Gu, Yang Zhang, Long Chen, Jiao Guo & Wen-Hai Zhang. (2014) Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer. Cancer Chemotherapy and Pharmacology 75:2, pages 301-308.
Crossref
Crossref
Sarah Mombelli, Fabrice Kwiatkowski, Catherine Abrial, Qian Wang-Lopez, Paul de Boissieu, Christian Garbar, Armand Bensussan & Hervé Curé. (2015) Prognostic Factors in Operable Breast Cancer Treated with Neoadjuvant Chemotherapy: Towards a Quantification of Residual Disease. Oncology 88:5, pages 261-272.
Crossref
Crossref
Vahit Ozmen, Ajlan Atasoy, Atilla Bozdogan, Maktav Dincer, Yesim Eralp & Sitki Tuzlali. (2015) Prognostic value of receptor status change following neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Treatment Communications 4, pages 89-95.
Crossref
Crossref
JIA YI WU, WEI GUO CHEN, XIAO SONG CHEN, OU HUANG, JIAN RONG HE, LI ZHU, YAFEN LI & KUN WEI SHEN. (2014) Long-term outcomes following adjuvant endocrine therapy in breast cancer patients with a positive-to-negative change of hormone receptor status following neoadjuvant chemotherapy. Molecular and Clinical Oncology 2:6, pages 997-1002.
Crossref
Crossref
Jia Yi Wu, Wei Guo Chen, Xiao Song Chen, Ou Huang, Jian Rong He, Li Zhu, Yafen Li, Kun Wei Shen, Louis W.C. Chow, Wings T.Y. Loo, Christopher Y.C. Chow & William Tsang. (2014) Outcomes of Adjuvant Endocrine Therapy and Hormone Receptor Status Change following Neoadjuvant Chemotherapy in Breast Cancer Patients. The International Journal of Biological Markers 29:4, pages 380-386.
Crossref
Crossref
Qiang Huo, Ning Zhang, Xiaolong Wang, Liyu Jiang, Tingting Ma & Qifeng Yang. (2013) Effects of Ambient Particulate Matter on Human Breast Cancer: Is Xenogenesis Responsible?. PLoS ONE 8:10, pages e76609.
Crossref
Crossref
Sheng Chen, Can-Ming Chen, Ke-Da Yu, Ruo-Ji Zhou & Zhi-Ming Shao. (2012) Prognostic Value of a Positive-to-negative Change in Hormone Receptor Status after Neoadjuvant Chemotherapy in Patients with Hormone Receptor–positive Breast Cancer. Annals of Surgical Oncology 19:9, pages 3002-3011.
Crossref
Crossref
Zhonghua Shi, Ting Zhang, Lei Zhang, Jing Zhao, Jian Gong & Chun Zhao. (2012) Increased microRNA-221/222 and decreased estrogen receptor α in the cervical portion of the uterosacral ligaments from women with pelvic organ prolapse. International Urogynecology Journal 23:7, pages 929-934.
Crossref
Crossref
David M. Gershenson, Charlotte C. Sun, Revathy B. Iyer, Anais L. Malpica, John J. Kavanagh, Diane C. Bodurka, Kathleen Schmeler & Michael Deavers. (2012) Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecologic Oncology 125:3, pages 661-666.
Crossref
Crossref
Judith Neumaier & Andreas Schäfer. (2012) Eine neoadjuvante Chemotherapie kann den Hormonrezeptor-Status beeinflussen. Im Focus Onkologie 15:4, pages 26-27.
Crossref
Crossref